Skyrizi's At-Home Crohn's Start Removes an Infusion Hurdle

AbbVie can now offer some Crohn's disease patients a fully self-administered Skyrizi regimen from the start of treatment. The U.S. Food and Drug Administration approved subcutaneous induction on October 23, replacing the need to begin with intravenous infusions for adults with moderately to severely active disease.

The new induction schedule delivers 720 milligrams through an on-body injector at weeks 0, 2, 4 and 8. Maintenance begins at week 12 and continues with the on-body injector every eight weeks. Intravenous induction remains an option, with 600-milligram infusions at weeks 0, 4 and 8.

Approval rested on AFFIRM, a randomized, double-blind Phase 3 trial of 274 patients assigned two to one to subcutaneous Skyrizi or placebo. Across the full study population, 56% of Skyrizi patients reached clinical remission at week 12, compared with 30% on placebo. Endoscopic response, which measures improvement visible inside the bowel, was 43% with Skyrizi and 15% with placebo.

Results were strongest among patients who had not previously failed an advanced therapy. In that group, 74% reached clinical remission versus 27% on placebo, while 60% achieved endoscopic response versus 15%. Among patients with a prior advanced-therapy failure, remission was 45% with Skyrizi and 31% with placebo, and endoscopic response was 33% versus 15%. The smaller gap in the treatment-experienced group is an important qualification to the headline result.

AbbVie said the safety profile was generally consistent with Skyrizi's established Crohn's profile and identified no new safety risks in the induction study. The label still carries warnings about serious allergic reactions, infections and liver problems. The FDA also changed tuberculosis language across approved indications: clinicians may now decide whether testing is needed before treatment rather than following a universal testing requirement.

For patients, the benefit is practical as well as clinical. Starting at home can remove infusion-center appointments and keep the route of administration consistent from induction through maintenance. AbbVie cited surveys in which 88% of 186 Crohn's patients found its on-body injector easy to use, although that user-experience evidence is separate from the placebo-controlled efficacy trial.

For investors, approval strengthens a large immunology franchise but does not reveal the speed of paid uptake. Management previously indicated that formulary acceptance can take 60 to 90 days, which would push much of the commercial effect beyond the immediate quarter. Competition also matters: Johnson & Johnson's Tremfya already offers subcutaneous and intravenous induction in Crohn's disease.

The next useful evidence will be payer access, prescription adoption and Skyrizi sales after the regimen has been available for a full quarter. The approval removes a meaningful treatment hurdle; it does not by itself quantify incremental revenue.